Skip to main content

Recent News

Canadian OBRI study in 692 RA pts shows pts treated w/ triple DMARD (MSH) stayed on Rx longer (15 mos) compared to MTX+LEF (9.6 mos); not significant but MTX/SSZ/HCQ had signif lower DAS28 @ 6 mos (3.4 vs 3.9) & at 12 mos (3.2 vs 3.5, p=0.0005) https://t.co/ieHeXvgj3n https://t.co/MEMA1nrUpy
Dr. John Cush @RheumNow (  View Tweet)
Join us 4/16 for Tuesday Night Rheumatology at 6:30pm ET. This week we'll be focusing on Vasculitis Mavens with: Vasculitis & Pregnancy - Catherine Sims, MD GPA Management in 2024 - Anisha Dua, MD, MPH Treat to Target in Vasculitis - Philip Seo, MD https://t.co/6IaCdCodGf https://t.co/HlZ8OiZWc4
Dr. John Cush @RheumNow (  View Tweet)
Karoshi - {Japanese 過労死: Death by Being Overworked} Over the last few decades, Japanese workers were collapsing dead at their desks or committing suicide due to the high stress stemming from their jobs; Japan coined this phenomenon, “Karoshi.” https://t.co/jhzWXtSBQT https://t.co/uSgUWZO3X5
Dr. John Cush @RheumNow (  View Tweet)
JAMA: SLE Review Drs.Siegel & Sammaritano (from HSS in NYC) published an impressive overview of SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide. https://t.co/byr1hRA6rV https://t.co/wZeIdfTlH0
Dr. John Cush @RheumNow (  View Tweet)
Pearl: Patients with persistent TMJ pain are more likely to have fibromyalgia than inflammatory or degenerative arthritis (as the underlying cause of their chronic pain) https://t.co/G43rxKVHus https://t.co/4mCu7b0PGn
Dr. John Cush @RheumNow (  View Tweet)
IL-1 recept accessory protein (IL1RAP) shown to block mediators (IL-1, IL33, IL36) that may drive systemic sclerosis. In vitro, IL1RAP inhibited fibroblasts and endothelial cells; in mouse models of SSc anti-IL1RAP decr dermal & pulmonary fibrosis. https://t.co/6YE02P4rjR https://t.co/mzw7t88Jzl
Dr. John Cush @RheumNow (  View Tweet)
SLE in JAMA (authored by Drs Siegel & Sammaritano at HSS), impressive, full-read review, Covers: - Presentations: skin, Jts, brain, heme, etc - Treatments - Prognosis - Complications: CV, infx, CA - FAQs https://t.co/7WHYK3DgIf https://t.co/pC2MSCpn52
Dr. John Cush @RheumNow (  View Tweet)
Polycyclic Aromatic Hydrocarbons Increase Lupus Risk A case-controlled study shows environmental exposure to polycyclic aromatic hydrocarbons (PAH) may increase the risk of developing systemic lupus erythematosus (SLE). https://t.co/AuYazGtamr https://t.co/S96LAuGtba
Dr. John Cush @RheumNow (  View Tweet)
Join us 4/16 for Tuesday Night Rheumatology at 6:30pm ET. This week we'll be focusing on Vasculitis Mavens with: Vasculitis & Pregnancy - Catherine Sims, MD GPA Management in 2024 - Anisha Dua, MD, MPH Treat to Target in Vasculitis - Philip Seo, MD https://t.co/5tvMJ5P2FC https://t.co/sk8Te3iEIy
Dr. John Cush @RheumNow (  View Tweet)
Best Imaging in Giant Cell Arteritis - US, PET, MRI? Imaging is often instrumental in diagnosing and staging patients diagnosed with giant cell arteritis (GCA). https://t.co/LXVB6cHDfO https://t.co/ArLNdEPuVx
Dr. John Cush @RheumNow (  View Tweet)
This study examined the risk of neuroinflammatory disease after initiation of b/tsDMARDs Overall risk of neuroinflammatory events among new users of TNF inhibitors did not differ substantially as compared to new users of other b/tsDMARDs In AC&R https://t.co/8rGgZmpq9c https://t.co/5gxuWBctBL
ACR_Journals @ACR_Journals (  View Tweet)
Korean National Insurance claims study (2010-18) of NSAID use and CV events found among 19,775 RA pts (F/U 98290 PYs); there were 1663 cases of CV evens. Increasing NSAID doses incr incident CVD(adjHR 1.10); including CVA (aHR 1.09). CHF (aHR 1.12) https://t.co/mdRKYMQq1s https://t.co/36i2KT4j5A
Dr. John Cush @RheumNow (  View Tweet)
LEGISLATION: In the USA, betw 2019-2023, 13 policies introduced in 7 different states to encourage nonpharmatologic measures for pain management (PT, CBT, acupuncture, chiropractic, etc). Only 2 were enacted, 3 in progress, 1 vetoed, 7 failed https://t.co/hYK3pRHG5D https://t.co/28PHVUiTD3
Dr. John Cush @RheumNow (  View Tweet)

ICYMI: Sex Disparities in PsA/SpA

Dr. Eder delivered an illuminating talk at RheumNow Live 2024 on sex differences in psoriatic arthritis; the disease may manifest differently in men and women, and therapeutic responses may differ between the sexes.

Read Article
I’m seeing some “free market” simps defending Nature’s 12k open access fees. Guess it’s time to bring this back around. https://t.co/sPW2qHN5m8
Dr. Glaucomflecken @DGlaucomflecken (  View Tweet)
Tuesday Night Rheumatology- Psoriatic Arthritis - Hot Topics Missed this past week's TNR? We've got you covered. https://t.co/uXUnKFdp9o https://t.co/TJcycELCPg
Dr. John Cush @RheumNow (  View Tweet)
JAMA: SLE Review Drs.Siegel & Sammaritano (from HSS in NYC) published an impressive overview of SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide. https://t.co/H9M3KPDkhf https://t.co/WBMjKZzziX
Dr. John Cush @RheumNow (  View Tweet)
BASDAI tends to be higher in women while there is no appreciable difference in ASDAS scoring in men compared to women. Dr. L. Eder believes this could be due to the pain scoring in both indices. #RNL2024 @RheumNow @lihi_eder https://t.co/PSnFwX3eHu

Dr. John Cush @RheumNow (  View Tweet)

What Term to you prefer to use (in your charts)?

Dr. John Cush @RheumNow (  View Tweet)